en · de · es · fr · pt
sr9009-notes.peptides6908.com › Data › Sr9009 Handling And Quality Control — Practical Notes

Sr9009 Handling And Quality Control — Practical Notes

By Editorial Desk · published 2026-05-31 · last reviewed 2026-07-19 · Data

circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-07-19. Anything still debated is marked as such rather than presented as settled.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Sr9009 at a glance

PropertyValueNotes
SynonymsSR9009; StenabolicStenabolic is an informal name
Common formCrystalline powderSupplied in milligram to gram quantities
Long-term storage-20 °C, desiccated, protected from lightReduces degradation
Detection techniqueLC-MS/MSCommon in anti-doping and research analysis
Regulatory statusProhibited in sport by WADANot approved for human therapeutic use

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Related pages on this site

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Background from the literature

Creatine transporter deficiency (CTD) is an inborn error of creatine metabolism in which creatine is not properly transported to the brain and muscles due to defective creatine transporters. CTD is an X-linked disorder caused by mutation in SLC6A8. SLC6A8 is located at Xq28. Hemizygous males with CTD express speech and behavior abnormalities, intellectual disabilities, development delay, seizures, and autistic behavior. Heterozygous females with CTD generally express fewer, less severe symptoms. CTD is one of three different types of cerebral creatine deficiency (CCD). The other two types of CCD are guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency. Clinical presentation of CTD is similar to that of GAMT and AGAT deficiency. CTD was first identified in 2001 with the presence of a hemizygous nonsense change in SLC6A8 in a male patient.

Otherwise, the carbonyl branch is homologous between the two domains and consists of the reduction of another molecule of CO2 to a carbonyl residue bound to an enzyme, catalyzed by the CO dehydrogenase/acetyl-CoA synthase. This key enzyme is also the catalyst for the formation of acetyl-CoA starting from the products of the previous reactions, the methyl and the carbonyl residues. This carbon fixation pathway requires only one molecule of ATP for the production of one molecule of pyruvate, which makes this process one of the main choice for chemolithoautotrophs limited in energy and living in anaerobic conditions.

== Function == Mechanical stress is continuously placed on the oral environment by actions such as eating, drinking and talking. The mouth is also subject to sudden changes in temperature and pH meaning it must be able to adapt to change quickly. The mouth is the only place in the body which provides the sensation of taste. Due to these unique physiological features, the oral mucosa must fulfil a number of distinct functions.

In the United States, like other AAS, stanozolol is classified as a controlled substance under federal regulation; they were included as Schedule III controlled substances under the Anabolic Steroids Control Act of 1990 which was passed as part of the Crime Control Act of 1990.

In the skull, a supratemporal fossa (excavation) is present in front of the supratemporal fenestra, the main opening in the rear skull roof Epipophyses, obliquely backward-pointing processes on the rear top corners of the anterior (front) neck vertebrae behind the atlas and axis, the first two neck vertebrae Apex of a deltopectoral crest (a projection on which the deltopectoral muscles attach) located at or more than 30% down the length of the humerus (upper arm bone) Radius, a lower arm bone, shorter than 80% of humerus length Fourth trochanter (projection where the caudofemoralis muscle attaches on the inner rear shaft) on the femur (thigh bone) is a sharp flange Fourth trochanter asymmetrical, with distal, lower, margin forming a steeper angle to the shaft On the astragalus and calcaneum, upper ankle bones, the proximal articular facet, the top connecting surface, for the fibula occupies less than 30% of the transverse width of the element Exoccipitals (bones at the back of the skull) do not meet along the midline on the floor of the endocranial cavity, the inner space of the braincase In the pelvis, the proximal articular surfaces of the ischium with the ilium and the pubis are separated by a large concave surface (on the upper side of the ischium a part of the open hip joint is located between the contacts with the pubic bone and the ilium) Cnemial crest on the tibia (protruding part of the top surface of the shinbone) arcs anterolaterally (curves to the front and the outer side) Distinct proximodistally oriented (vertical) ridge present on the posterior face of the distal end of the tibia (the rear surface of the lower end of the shinbone) Concave articular surface for the fibula of the calcaneum (the top surface of the calcaneum, where it touches the fibula, has a hollow profile) Nesbitt found a number of further potential synapomorphies and discounted a number of synapomorphies previously suggested. Some of these are also present in silesaurids, which Nesbitt recovered as a sister group to Dinosauria, including a large anterior trochanter, metatarsals II and IV of subequal length, reduced contact between ischium and pubis, the presence of a cnemial crest on the tibia and of an ascending process on the astragalus, and many others.

Sources: en.wikipedia.org

Further detail

Tofisopam has also appeared in Washington State’s equine drug regulations. Washington State regulatory documents list ‘’‘Grandaxain’’’ and ‘’‘Seriel’’’ and as a Class 2 substance within equine medicine. Tofisopam has been shown to act as an inhibitor of the liver enzyme CYP3A4, and some researches suspect that this could cause dangerous drug interactions with other medications metabolised by this enzyme, although the clinical significance of these findings remains unclear.

Difloxacin (INN), marketed under the trade name Dicural, is a second-generation, synthetic fluoroquinolone antibiotic used in veterinary medicine. It has broad-spectrum, concentration dependent, bactericidal activity; however, its efficacy is not as good as enrofloxacin or pradofloxacin.

=== Duration and exclusivity === Numerous health organizations, including, but not limited to, the CDC, WHO, National Health Service, Canadian Pediatric Society, American Academy of Pediatrics, and American Academy of Family Physicians, recommend breastfeeding exclusively for six months following birth, unless medically contraindicated. Exclusive breastfeeding is defined as "an infant's consumption of human milk with no supplementation of any type (no water, no juice, no nonhuman milk and no foods) except for vitamins, minerals and medications." Supplementation with human donor breastmilk may be indicated in some specific cases, as discussed below. After solids are introduced at around six months of age, continued breastfeeding is recommended. The American Academy of Pediatrics recommends that babies be breastfed at least until 12 months, or longer if both the mother and child wish. The World Health Organization's guidelines recommend "continue[d] frequent, on-demand breastfeeding until two years of age or beyond. The American Academy of Pediatrics policy statement also supports continued breastfeeding to 2 years and older, depending on the mother and child. Extended breastfeeding means breastfeeding after the age of 12 or 24 months, depending on the source. In Western countries such as the United States, Canada, and Great Britain, extended breastfeeding is relatively uncommon and can provoke criticism. Globally exclusive breastfeeding rose from 37.0% to 47.4% between 2012 and 2024;.

== Early life == Arsène Charles Ernest Wenger was born on 22 October 1949 in Strasbourg, Bas-Rhin, the youngest of three children born to Alphonse and Louise Wenger. He lived in Duppigheim during the 1950s, but spent most of his time in the neighbouring village of Duttlenheim, 16 km (10 miles) south-west of Strasbourg. Arsène's father, Alphonse, like many Alsatians, was conscripted into the German Army by force following Germany's earlier annexation of the French region of Alsace-Lorraine. He was sent to fight on the Eastern Front in October 1944, at the age of 24. The Wenger family owned an automobile spare parts business and a bistro named La Croix d'Or. In his book, My Life in Red and White, Wenger says the "alcohol, brawling and violence" of the bistro's patrons sparked his early interest in human psychology. His parents had difficulty looking after their children, but Duttlenheim was a village where everyone took care of the young; Wenger compared it in later years to a kibbutz. Before Wenger started school, he expressed himself in the local Alsatian dialect of Low Alemannic German. The primary school which Wenger attended was run by the Catholic Church, and as one of its brightest students, he later was accepted into a secondary school in Obernai. According to his father, who also managed the village team, Wenger was introduced to football "at about the age of six". He was taken to games in Germany, where he held an affection for Borussia Mönchengladbach.

=== Extraction === After cooking, the alkaline liquid (known as nejayote from Nahuatl nexayotl - nextli 'ash' y ayotl 'liquid'), containing dissolved hull, starch, and other corn matter, is decanted and discarded (or sometimes used for making amate bark paper). The kernels are washed thoroughly of remaining nejayote, which has an unpleasant flavor. The pericarp is then removed, leaving the endosperm of the grain with or without the germ, depending on the process. This hulling is performed by hand, in traditional or very small-scale preparation, or mechanically, in larger scale or industrial production. The prepared grain is called hominy, mote, or nixtamal. Nixtamal has many uses, contemporary and historic. Whole nixtamal may be used fresh or dried for later use. Whole nixtamal is used in the preparation of pozole, menudo, and other foods. Ground fresh nixtamal is made into masa (nixtamal dough) and used to make tortillas, tamales, and pupusas. Dried and ground, it is called masa harina or instant masa flour, and is reconstituted and used like masa. The term hominy may refer to whole, coarsely ground, or finely ground nixtamal, or to a cooked porridge (also called grits) prepared from any of these. Samp is similar to grits, but a product of a different process.

Sources: en.wikipedia.org

Supporting material

=== Dithiols === 1,3-Propanedithiol and 1,2-ethanedithiol are reagents in organic chemistry. Dimercaptosuccinic acid is a chelating agent. Lipoic acid, a naturally occurring modification of 1,3-propanedithiol, is a cofactor for many enzymes. Dithiothreitol is a reagent in biochemistry.

Bacteria encode evolutionary predecessors of cGAS, called cGAS/DncV-like nucleotidyltransferases (CD-NTases), which detect bacteriophage infection and produce diverse nucleotide second messengers. The regulation of bacterial CD-NTase activation remains an open question. Recent research has shown that CD-NTase-associated protein 2 (Cap2) primes bacterial CD-NTases for activation through a ubiquitin transferase-like mechanism. A cryo-electron microscopy structure of the Cap2–CD-NTase complex reveals Cap2 as an all-in-one ubiquitin transferase-like protein, with distinct domains resembling eukaryotic E1 and E2 proteins. The structure captures a reactive-intermediate state with the CD-NTase C-terminus positioned in the Cap2 E1 active site and conjugated to AMP. Cap2 conjugates the CD-NTase C-terminus to a target molecule that primes the CD-NTase for increased cGAMP production. Additionally, a specific endopeptidase, Cap3, balances Cap2 activity by cleaving CD-NTase–target conjugates. This research demonstrates that bacteria control immune signaling using an ancient, minimized ubiquitin transferase-like system, providing insights into the evolution of E1 and E2 machinery across domains of life.

=== Active site === There are two distinct bi-lobed active site cavities located at the bottom edge of each monomer’s αβαβα core. Identical six-residue loops, which meet at the dimer interface, separate the two active sites from each other. The loops being with Thr132 in the active site and ends with a cis-peptide bond to Pro138. A Met137 residue plugs a hole in the other monomer’s active site. Therefore, the active site is buried except for a 16 Å CoA-binding tunnel that connects the catalytic surface to the outer surrounding milieu. The width of the tunnel is too narrow for the aromatic substrates and products that must pass through it, implying that there must be some dynamic mobility within and around the tunnel when placed in solution. The active site contains a conserved catalytic triad of Cys164, His303 and Asn336. These residues aid in multiple decarboxylation and condensation reactions, with Cys164 acting as the active site nucleophile. Phe215 and Phe265 are two other important amino acids that act as “gatekeepers” to block the lower protein of the opening between the CoA-binding tunnel and the active site cavity. This limits the access of water to the active site while accommodating substrates and intermediates of varying shapes and sizes. Phe215 also orients the substrates at the active site during elongation of the polyketide intermediate.

The first season became available on HBO Max on December 1, 2020. The second season of the series airs exclusively on The CW, and premiered on August 10, 2021; it also debuted on HBO Max on December 10 the same year. The third season premiered on August 31, 2022. The season debuted on HBO Max on January 6, 2023.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

What does research-grade purity mean?

Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.

Why is SR9009 banned in sport?

Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

Network